U.S. Markets close in 4 hrs 58 mins

Peregrine to Report First Quarter Fiscal Year 2013 Financial Results Before Market on September 10, 2012

TUSTIN, CA--(Marketwire -09/04/12)- Peregrine Pharmaceuticals, Inc. (PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter of the fiscal year 2013 on September 10, 2012 before market and will host a conference call and webcast at 8:00 AM PDT (11:00 AM EDT). Peregrine's senior management will discuss financial results for the first quarter of fiscal year ended July 30, 2012 and will review progress of its clinical development programs, including an overview of the bavituximab data that will be presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology on September 7, 2012.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through September 24, 2012 by calling (855) 859-2056, or (404) 537-3406 and using passcode 27367274.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.